a Department of Hematology and Medical Oncology, Winship Cancer Institute , Emory University , Atlanta , GA , USA.
Expert Rev Hematol. 2016 Jun;9(6):553-61. doi: 10.1080/17474086.2016.1180972. Epub 2016 May 13.
Diffuse large B cell lymphoma (DLBCL) is characterized by genetic, genomic and clinical heterogeneity. Autoimmune diseases (AIDs) have recently been shown to represent significant risk factors for development of DLBCL.
Studies that examined the relationships between AIDs and lymphoma in terms of pathogenesis, genetic lesions, and treatment were identified in the MEDLINE database using combinations of medical subject heading (MeSH) terms. Co-authors independently performed study selection for inclusion based on appropriateness of the study question and nature of the study design and sample size. Expert commentary: Identification of AID as a substantial risk factor for DLBCL raises new questions regarding how autoimmunity influences lymphomagenesis and disease behavior. It will be important to identify whether DLBCL cases arising in the setting of AID harbor inferior prognoses, and, if so, whether they also exhibit certain molecular abnormalities that may be targeted to overcome such a gap in clinical outcomes.
弥漫性大 B 细胞淋巴瘤（DLBCL）的特征是遗传、基因组和临床异质性。最近的研究表明，自身免疫性疾病（AIDs）是 DLBCL 发生的重要危险因素。
使用医学主题词(MeSH)组合，在 MEDLINE 数据库中确定了研究发病机制、遗传病变和治疗方面的 AIDs 与淋巴瘤之间关系的研究。共同作者根据研究问题的适当性、研究设计和样本量的性质，独立进行了研究选择。
将 AID 确定为 DLBCL 的一个重要危险因素，提出了新的问题，即自身免疫如何影响淋巴瘤的发生和疾病行为。重要的是要确定在 AID 背景下发生的 DLBCL 病例是否预后较差，如果是这样，它们是否也表现出某些可能针对克服这种临床结局差距的特定分子异常。
